760 related articles for article (PubMed ID: 18261916)
41. Soluble triggering receptor expressed on myeloid cells-1 for diagnosing empyema.
Bishara J; Goldberg E; Ashkenazi S; Yuhas Y; Samra Z; Saute M; Shaked H
Ann Thorac Surg; 2009 Jan; 87(1):251-4. PubMed ID: 19101307
[TBL] [Abstract][Full Text] [Related]
42. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure.
McDowell G; Gupta S; Dellerba M; Coppinger T; Levy RD; Keevil BG
Ann Clin Biochem; 2004 Nov; 41(Pt 6):491-3. PubMed ID: 15588442
[TBL] [Abstract][Full Text] [Related]
43. [Clinical investigation of the diagnostic value of interferon-gamma, interleukin-12 and adenosine deaminase isoenzyme in tuberculous pleurisy].
Tian RX; Gao ZC
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jul; 27(7):435-8. PubMed ID: 15312552
[TBL] [Abstract][Full Text] [Related]
44. Differentiating between malignant and idiopathic pleural effusions: the value of diagnostic procedures.
Alemán C; Sanchez L; Alegre J; Ruiz E; Vázquez A; Soriano T; Sarrapio J; Teixidor J; Andreu J; Felip E; Armadans L; Fernández De Sevilla T
QJM; 2007 Jun; 100(6):351-9. PubMed ID: 17525131
[TBL] [Abstract][Full Text] [Related]
45. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
Schulze G
Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
[TBL] [Abstract][Full Text] [Related]
47. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
48. [Diagnostic utility of carcinoembryonic antigen, neuron-specific enolase and squamous cell carcinoma antigen in malignant pleural effusion].
Sánchez de Cos Escuín J; López Parra S; Disdier Vicente C; Martín Vicente MJ; Masa Jiménez JF; Domínguez Retortillo C
An Med Interna; 1996 Aug; 13(8):369-73. PubMed ID: 8983362
[TBL] [Abstract][Full Text] [Related]
49. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
[TBL] [Abstract][Full Text] [Related]
50. Usefulness of soluble interleukin 2 receptor in differentiating tuberculous and carcinomatous pleural effusions.
Chang SC; Hsu YT; Chen YC; Lin CY
Arch Intern Med; 1994 May; 154(10):1097-101. PubMed ID: 8185423
[TBL] [Abstract][Full Text] [Related]
51. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.
Bielsa S; Esquerda A; Salud A; Montes A; Arellano E; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2009 Jul; 20(4):383-6. PubMed ID: 19524179
[TBL] [Abstract][Full Text] [Related]
52. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
53. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
54. [Diagnostic characteristics of the CA-50 and CA 72-4 tumor markers in body fluids. Use in the diagnosis of malignant effusions].
Lemberger J; Libman E; Lászlo-Klein M; Skenderović S; Novak A
Med Pregl; 1991; 44(3-4):126-9. PubMed ID: 1921859
[TBL] [Abstract][Full Text] [Related]
55. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
Lee WY
Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
[TBL] [Abstract][Full Text] [Related]
56. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer.
Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H
Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
58. Glucose transporter 1 protein detected by enzyme-linked immunosorbent assay and immunocytochemistry: a useful diagnostic tool for malignant pleural effusions.
Liao ND; Chiang TA; Lee WY
Cancer Cytopathol; 2013 Dec; 121(12):695-702. PubMed ID: 23861325
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions.
Zhou WB; Bai M; Jin Y
Int J Tuberc Lung Dis; 2009 Mar; 13(3):381-6. PubMed ID: 19275801
[TBL] [Abstract][Full Text] [Related]
60. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
Weinberger R; Appel B; Stein A; Metz Y; Neheman A; Barak M
Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
